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Objective: To aid in the timely diagnosis of patients who present with clinically isolated 
syndrome (CIS).
Patients and methods: We studied 25 patients (18 women, 7 men), originally presented 
in our clinic with a CIS suggestive of multiple sclerosis (MS). All patients underwent the full 
investigation procedure including routine tests, serology, cerebrospinal ﬂ  uid (CSF) examinations, 
evoked potentials (EPs), and magnetic resonance imaging (MRI) of brain and cervical spinal 
cord. Patients were imaged at baseline, and every three months thereafter up to a year.
Results: The CIS was consisted of optic neuritis in 12 cases, incomplete transverse myelitis 
(ITM) in 7 cases, Lhermitte sign in 2 cases, internuclear ophthalmoplegia (INO) in 2 cases, 
mild brainstem syndrome in 1 case, and tonic-clonic seizures in 1 case. Using the baseline and 
three-month scans 18/25 (72%) patients developed deﬁ  nite MS in one year of follow up while 
7 (28%) had no further ﬁ  ndings during this observation period. Immunomodulatory treatments 
were applied to all deﬁ  nite MS patients.
Conclusion: In light of new treatments available, MRIs at 3 month intervals are helpful to 
obtain the deﬁ  nite diagnosis of MS as early as possible.
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Introduction
Multiple sclerosis (MS) is a clinical diagnosis based on the dissemination of lesions of 
the central nervous system (CNS) in time and space (Poser and Brinar 2001). Recent 
proposed diagnostic criteria for MS utilize MRI ﬁ  ndings to document dissemination 
of CNS lesions in time and space (McDonald et al 2001; Polman et al 2005). Optic 
neuritis (ON) may be the heralding manifestation of MS (ONSG 1991; Hickman et al 
2002). More than 50% of adult patients who present with isolated ON will eventu-
ally develop other signs of MS (ONSG 1997). The risk stratiﬁ  cation for the future 
development of MS in patients presenting with ON can be assessed by the number of 
white matter lesions on the baseline cerebral MRI study (Bhatti et al 2005). The risk 
is increased in women and in those patients who have oligoclonal bands (OCB) in the 
cerebrospinal ﬂ  uid (CSF) (Ghezzi et al 1999).
Incomplete transverse myelitis (ITM) can be the presenting feature of MS. Patients 
with ITM who develop MS are more likely to have asymmetric clinical ﬁ  ndings, 
predominant sensory symptoms with relative sparing of motor systems, spinal cord 
lesions extending over less than two spinal segments, abnormal brain MRI, and OCB 
in the CSF (Miller et al 1989; TMC 2002). Measurement of spinal cord atrophy that 
reﬂ  ects destructive, irreversible pathology in patients presenting with ITM has impor-
tant implications for the early treatment of MS (Lin et al 2004).Therapeutics and Clinical Risk Management 2008:4(3) 628
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Central nervous system involvement in MS may be 
difﬁ  cult to differentiate from other autoimmune diseases such 
as systemic lupus erythematosus (SLE), antiphospholipid 
syndrome (APS), and Sjogren syndrome (SS). Thus, a large 
number of patients with APS or SLE may be misdiagnosed 
as MS, but the exact proportion is unknown and may receive 
inappropriate treatment (Ferreira et al 2005). A retrospective 
study in 82 patients with primary Sjogren syndrome reported 
that 40.2% had brain involvement, 15.8% optic neuropathy, 
and 35.4% spinal cord involvement (Delalande 2004). Thus, 
the differential diagnosis may require careful assessment of 
all clinical and MRI ﬁ  ndings, serological results, and CSF 
analysis (Reske et al 2005).
Our objective was to aid in the timely diagnosis of MS in 
patients who presented with CIS and thus employ the proper 
treatment early during the course of the disease.
Patients and methods
We studied 25 consecutive patients (18 women, 7 men), age 
30.6 (range: 17–49) presented in our clinic with CIS sugges-
tive of MS. The inclusion and exclusion criteria of the CIS 
patients are listed in Table 1. The clinical, laboratory, and 
imaging ﬁ  ndings were studied in all patients. Laboratory 
investigations included complete blood count, serum values 
of liver enzymes, bilirubin, albumin, glucose, creatinine, 
and urine analysis. In addition, erythrocyte sedimentation 
rate, C-reactive protein, antinuclear antibodies (ANA), 
double-stranded DNA (ds-DNA), complement C3/C4, and 
anti-cardiolipin (ACL) antibodies were also perfomed.
All patients were evaluated for MS with CSF serology 
(cells, protein, glucose, IgG index), visual evoked poten-
tials (VEPs), somatosensory evoked potentials (SEPs), and 
brain and cervical spinal cord MRI. Patients were imaged 
at baseline, at three month intervals, and one year. CSF 
oligoclonal bands were not included in the evaluation since 
it is not an available test in our hospital laboratory. For MS 
diagnosis, the revised McDonald criteria were employed 
(Polman et al 2005). Dissemination in space was demon-
strated by either MRI alone when three of the following 
conditions were met: a) at least one gadolinium-enhancing 
lesion or nine T2 hyperintense lesions if there was no 
gadolinium enhancing lesion; b) at least one infratentorial 
lesion; c) at least one juxtacortical lesion; and d) at least three 
periventricular lesions, or two or more MRI-detected lesions 
consistent with MS plus elevated CSF IgG index. Dissemi-
nation in time was demonstrated by either MRI (detection 
of gadolinium enhancing abnormality at least 3 months 
after the onset of the initial clinical event and if not at the 
site corresponding to the initial event detection of a new T2 
lesion if it appeared at any time compared with the baseline 
scan performed at least 30 days after the onset of the initial 
clinical event), or by a second clinical attack.
None of the studied patients had history of head trauma, 
neuropsychiatric disorder, diabetes mellitus, hypertension, 
thalassemia, iron and B12 deﬁ  ciency, cardiac, hepatic and 
renal failure (Table 1). Finally, the protocol was approved 
by the Institutional Review Board Committee.
Results
The characteristics of all CIS patients are depicted in Table 2. 
There were 25 patients (18 women, 7 men), of 30.6 years 
mean age (range 17–49). The mean age of patients at onset 
of CIS varied from 26.9 years for ON to 29.2 years for the 
patient with seizures. The mean follow-up time was 18.9 
months in patients with ON, 17.5 months in patients with 
ITM, 18 months in patients with brainstem syndrome. The 
mean disease severity on the expanded disability status scale 
(EDSS) performed at least one month after the CIS varied 
from 0.41 to 1. Only 12 woman had isolated ON, 7 had 
ITM, 3 had mild brainstem syndrome (2 with internuclear 
ophthalmoplegia (INO), 1 with dysarthria), and 1 had sudden 
onset of tonic-clonic seizures. The predominant neurological 
examination ﬁ  ndings during the acute phase of the CIS were: 
reduced unilateral visual acuity in the patients with ON, 
paraparesis, Lhermitte sign, sensory symptoms, diplopia, 
dysarthria, and hemiparesis as shown in Table 3.
The paraclinical data of the patients are shown in 
Table 4. Twenty four patients had abnormal brain MRI 
consisted of periventricular MS-like white matter lesions 
and 9 (36%) patients had evidence of myelitis. Both brain 
and cervical cord MRI were positive in 7 cases (28%). 
Table 1 List of inclusion and exclusion criteria
Inclusion criteria  Exclusion criteria
Optic neuritis  Head trauma
Diplopia Neuropsychiatric  disorder
Internuclear opthalmoplegia  Diabetes mellitus
Myelitis Hypertension
Hemiparesis-paraparesis Cardiac  failure
Dysarthria Hepatic  failure
Sensory symptoms  Renal failure
MRI criteria:  Thalassemia,
  a. 1 GD enhancing lesion  Sickle cell disease,
  b. 1 infratentorial lesion  Iron deﬁ  ciency,
  c. 1 juxtacortical lesion  B12 deﬁ  ciency
  d. 3 periventricular lesions 
Abbreviation: MRI, magnetic resonance imaging.Therapeutics and Clinical Risk Management 2008:4(3) 629
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VEP’s were abnormal in 16 (64%) and SEP’s in 6 (24%) 
patients. Nineteen patients (76%) had increased IgG index, 
while in 6 patients it was normal.
Serological features of the patients are demonstrated in 
Table 5. ANA were positive in 5 (20%) and anti-ds-DNA in 
2 (8%) of patients, but no patient had low complement (C3 
or C4). ACL-ab was positive in only 3 (12%) patients.
Using the baseline and three-month MRI scans and the 
clinical and paraclinical data, 72% of patients with CIS 
developed deﬁ  nite MS according to the revised McDonald’s 
criteria within one year, while 28% had no further neurologi-
cal and MRI ﬁ  ndings during this observation period.
Discussion
Patients with CIS may develop MS (Miller et al 2005). Clini-
cally the identiﬁ  cation of patients with a CIS at high risk to 
develop clinically deﬁ  nite MS remains difﬁ  cult (Kieseier et al 
2005). Monthly brain MRI scans in patients with CIS showed 
that the majority of patients with an abnormal baseline scan 
were diagnosed with MS after three months (Pestalozza et al 
2005). Application of the new McDonald criteria to patients 
with CIS suggestive of MS doubled the rate of diagnosis of 
MS within one year of presentation (Dalton et al 2002). It 
has been suggested that monthly triple-dose Gd-enhanced 
MRIs accurately detected inﬂ  ammation which is an important 
factor in the pathogenesis of brain tissue loss in CIS patients 
(Paolillo et al 2004).
Although a CIS could be indicative of MS, it might occa-
sionally be the ﬁ  rst manifestation of systemic autoimmune 
diseases such as SLE, APS, and SS. In these cases not only 
the clinical presentation but the MRI ﬁ  ndings may be similar 
(Theodoridou and Settas 2006). Thus, serology tests, eg, 
ANA, C3, C4, and antiphospholipid antibodies, could help 
in the differential diagnosis of MS from the various connec-
tive tissue diseases. In the present study 20% of CIS patients 
had positive ANA and a few patients had other autoantibod-
ies but there were no other ﬁ  ndings to indicate evidence 
of SLE, primary SS, and APS according to the currently 
used criteria (Tan et al 1982; Wilson et al 1999; Vital et al 
2002). Presence of various autoantibodies such as ANA in 
the serum of patients with MS is a frequent ﬁ  nding (Specaile 
et al 2000). Brain MRI can be inconclusive in patients with 
CIS but intrathecal synthesis of OCB are helpful in estab-
lishing the diagnosis of MS (Sastre-Garriga et al 2003; Rot 
and Mesec 2006), thus the lack of OCB measurements is a 
limitation of our study. A new OCB test may also improve 
the conversion of a CIS to MS (Masjuan et al 2006). Predic-
tion of conversion from CIS to MS can be improved if CSF 
Table 2 Characteristics of CIS patients
 ON  ITM  Brainstem  syndrome
Sex ratio (female/male)  12/0  3/4  2/1
Age at diagnosis mean +/− SD (range)  29.5 ± 16 (17–46)  28.9 ± 8.7 (20–42)  29.6 ± 12 (24–49)
Age at onset of CIS mean +/− SD (range)  26.9 ± 10.3 (17–43)  28.7 ± 9.1 (19–37)  29.1 ± 9.6 (21–48)
Follow up time mean months (range)  18.9 (9–60)  17.5 (3–26)  18 (17–29)
Duration of disease mean months, (range)  20.7 (9–61)  19.3 (4–26)  19.5 (17–29)
Disease severity on EDSSa mean (range)  0.41 (0–1)  0.6 (0–2.5)  1 (1–1)
Abbreviations: CIS, clinically isolated syndrome; ON, optic neuritis; ITM, incomplete transverse myelitis; EDSS, expanded disability status scale.
Note: aEDSS was assessed at least one month after the CIS.
Table 3 Clinical data of CIS patients
Neurological symptoms and signs  No. of patients (%)
Optic neuritis  12 (48%)
Myelitis 7  (28%)
Internuclear opthalmoplegia  2 (8%)
Seizures 1  (4%)
Paraparesis 5  (25%)
Lhermitte sign  2 (8%)
Sensory symptoms  9 (36%)
Diplopia 3  (12%)
Dysarthria 1  (4%)
Hemiparesis 1  (4%)
Abbreviations: CIS, clinically isolated syndrome.
Table 4 Paraclinical data of CIS patients: Initial 2/25
Parameters (+) (−)
Initial brain MRI  23/25 (92%)  2/25 (8%)
Brain MRIa  24/25 (96%)  1/25 (4%)
Cervical SC MRIa  9 (36%)  16 (64%)
VEP's  16/25 (64%)  9/25 (36%)
SEP's  6/25 (24%)  19/25 (76%)
CSFb/WBC  1/25 (4%)  24/25 (96%)
CSFb/IgG INDEX  19/25 (76%)  6/24 (24%)
Abbreviations: CIS, clinically isolated syndrome; SC, spinal cord; VEP, visual evoked 
potentials; SEP, somatosensory evoked potentials; CSF, cerebrospinal ﬂ  uid.
Notes: aBrain and cervical SC MRIs were considered (+) when ﬁ  ndings were observed 
at any time during the 3 month intervals up to a year; bCSF serology was performed 
during the baseline evaluation.Therapeutics and Clinical Risk Management 2008:4(3) 630
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markers (either elevated tau or neuroﬁ  laments [NfHSMI35] 
are combined with MRI ﬁ  ndings (Brettschneider at al 2006). 
On the contrary, serum antimyelin antibodies did not seem 
to permit earlier diagnosis of MS (Lim et al 2005). Intrathe-
cal B-cell clonal expansion in the CSF of patients with CIS, 
often precedes both OCB and multiple MRI lesions and is 
associated with a high rate of conversion to deﬁ  nite MS 
(Qin et al 2003).
Conclusion
Patients with MS deserve an accurate diagnosis, because new 
effective immunomodulatory treatments could modify the 
disease progression. It is obvious that deﬁ  nite diagnosis of 
MS must be obtained as early as possible in order to initiate 
early immunomodulatory treatment. We believe that frequent 
MRI scans during the ﬁ  rst year after the CIS facilitate the 
early and accurate diagnosis of deﬁ  nite MS.
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